Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

[Background] Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating t...

Descripción completa

Detalles Bibliográficos
Autores: Serrano, César, Vivancos, Ana, López-Pousa, Antonio, Matito, Judith, Mancuso, Francesco M., Valverde, Claudia M., Quiroga, Sergi, Landolfi, Stefania, Castro, Sandra, Dopazo, Cristina, Sebio, Ana, Virgili, Anna C., Menso, María M., Martín-Broto, Javier, Sansó, Miriam, García-Valverde, Alfonso, Rosell, Jordi, Fletcher, Jonathan A., George, Suzanne, Carles, Joan, Arribas, Joaquín
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/236485
Acceso en línea:http://hdl.handle.net/10261/236485
Access Level:acceso abierto
Palabra clave:Circulating tumor DNA
Gastrointestinal stromal tumor
Imatinib
KIT
Liquid biopsy
PDGFRA
Sarcoma
Regorafenib
Sunitinib
Descripción
Sumario:[Background] Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating tumor (ct)DNA determination is expected to be an informative non-invasive dynamic biomarker in GIST patients.

Similares en LA Referencia